Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine.
#MORA CALAIR TRIAL#
We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.
Patel, R.D., A.C., S.G., D.A.M., K.Y.S., W.R.S.) and Janssen Research and Development, Beerse, Belgium (H.C., S.V., P.E.W., W.P.). Brinson) Josha Research, Bloemfontein, South Africa (J.L.) ViiV Healthcare, Research Triangle Park, NC (M.S.C., P.
Bettacchi), and Central Texas Clinical Research, Austin (C. Philibert) - both in France the National Center for Global Health and Medicine, Tokyo (S.O.) the University Health Network, University of Toronto, Toronto (S.W.), and GlaxoSmithKline, Mississauga (S.L.F., D.D.) - both in Ontario, Canada North Texas Infectious Disease Consultants, Dallas (C.
0 kommentar(er)
